Impact of genetic mutations and health plan access to therapies on treatment response and drug costs related to tyrosine kinase inhibitor treatment among patients …
E Jabbour, D Makenbaeva… - American Journal of …, 2018 - journals.lww.com
Objectives: This study assessed treatment responses and economic consequences of
limiting access to the second-generation BCR-ABL1 tyrosine kinase inhibitors (2G-TKI),
dasatinib and nilotinib, for treatment of chronic myelogenous leukemia, while taking into
account frequencies of genetic mutations that exhibit different sensitivities to the 2G-TKIs.
Methods: Frequencies of BCR-ABL1 mutations and the impact of mutations on responses to
2G-TKIs were obtained from published literature and used as inputs in a decision analytics …
limiting access to the second-generation BCR-ABL1 tyrosine kinase inhibitors (2G-TKI),
dasatinib and nilotinib, for treatment of chronic myelogenous leukemia, while taking into
account frequencies of genetic mutations that exhibit different sensitivities to the 2G-TKIs.
Methods: Frequencies of BCR-ABL1 mutations and the impact of mutations on responses to
2G-TKIs were obtained from published literature and used as inputs in a decision analytics …